33 results about "Campylobacter coli" patented technology

The invention discloses a fourteen-food-borne pathogenic bacterium multiplex PCR detection primer set and a kit. The detection primer set is composed of primer pairs for detecting salmonella, Shigella, Vibrio parahemolyticus, campylobacter jejuni, campylobacter coli, staphylococcus aureus, bacillus cereus, Listeria monocytogenes, yersinia enterocolitica, enterobacter sakazakii, Escherichia coli, vibrio cholerae, Escherichia coli O157, aeromonas hydrophila and internal positive control. A multiplex PCR detection method based on an ordinary PCR platform is built, multiplex PCR reactions are carried out on genomic DNA, extracted from a sample to be tested, of bacteria in the same reaction system through the primer pairs acquired through analysis and design, and whether the food-borne pathogenic bacteria are contained in the sample or not is judged through the electrophoretic analysis of reaction products.

The present invention relates to Salmonella enterica comprising at least one pgl operon of Campylobacter jejuni or a functional derivative thereof and presenting at least one N-glycan of Campylobacter jejuni or N-glycan derivative thereof on its cell surface. In addition, it is directed to medical uses and pharmaceutical compositions thereof as well as methods for treating and/or preventing Campylobacter and optionally Salmonella infections and methods for producing these Salmonella strains.

The invention discloses a double-antibody sandwich ELISA (enzyme-linked immuno sorbent assay) method for detecting listeria in food on the basis of monoclonal antibodies, belonging to the technical field of immunoassay. The method comprises the following steps: immunizing 8-week BALB mouse with prokaryotically expressed listeria monocytogenes P60 protein, and obtaining 15 strains of listeria specific monoclonal antibodies by immunization, fusion and multiple screening; respectively marking horse radish peroxidase HRP, and carrying out pairwise coupling by taking the listeria monocytogenes CMCC54003 as targets. The sandwich ELISA method which is established by screening different paired cross reactions and taking 2G7 as a coating antibody and 2H8-HRP as an enzyme labelled antibody has cross reactions to listeria including the listeria monocytogenes, and has no cross reactions to tested staphylococcus aureus, escherichia coli, escherichia coli O157, salmonella, enterobacter sakazakii, campylobacter jejuni and campylobacter coli. According to the method disclosed by the invention, the monoclonal antibodies having listeria specificity are prepared and the double-antibody sandwich ELISA method is established, and the method provides a technical means for specific rapid detection of the listeria in food.

The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, E. coli, Salmonella, Serratia, Proteus, Enterobacter, Citrobacter, Campylobacter and Pseudomonas. The present invention further provides methods of treating inflammatory bowel disease (IBD) and methods of treating enterobacterial infections using anti-flagellin antibodies in humans, other animals and birds.

The present invention relates to the use of probiotic microorganism in the manufacture of a composition for the prevention or reduction of gastrointestinal Camplylobacter infection in a mammalian animal. It also relates to a method for the prevention or reduction of gastrointestinal Campylobacter infection in a mammalian animal, the method comprising administering to said animal, a probiotic microorganism. The invention also relates to a probiotic microorganism, for use in preventing or reducing gastrointestinal Campylobacter infection in a mammalian animal.

The invention belongs to the field of microorganism molecular typing and particularly relates to a primer and a method for fast typing campylobacter jejuni. The primer includes 13 pairs of campylobacter jejuni primers. The primer is good in typing capacity, high in distinguishing index and capable of accurately typing the campylobacter jejuni. In addition, the method for fast typing the campylobacter coli is simple and fast to operate, good in stability and repeatability, capable of effectively assisting the clinical diagnosis of diseases infected by the campylobacter jejuni and ideal.

Multiplex PCR primers that can amplify the cdt genes of C. jejuni, C. coli, and C. fetus in a bacterial species-specific manner were prepared. Multiplex PCR with the primers was assessed using Campylobacter bacteria, other cdt gene-positive bacteria, and representative bacteria responsible for enteric infection. As a result, the present inventors' multiplex PCR using cdtB amplification primers was proven to enable simultaneous detection of different Campylobacter bacteria with high specificity. The methods of the present invention can identify Campylobacter at the bacterial species level in a single manipulation even when domestic animals or humans are infected with different bacterial species of Campylobacter.

The invention provides real-time fluorescence quantitative PCR (Polymerase Chain Reaction) primers and probe for detecting campylobacter coli. The sequences of the primers and probe are respectively shown in SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO.4. The invention also provides a method for carrying out fluorescence quantitative PCR detection on campylobacter coli by using the primers and probe, and a kit for detecting campylobacter coli. The detection method and the kit for detecting campylobacter coli provided by the invention have the advantages of accurate detection, high sensitivity, strong specificity, simplicity, convenience, quickness and good clinical specimen detection capability.

The invention discloses triplex PCR detection primers and a triplex PCR detection kit for cytolethal distending toxins A, B and C of Campylobacter. The Campylobacter involved in the invention comprises Campylobacter coli, Campylobacter jejuni and Campylobacter fitus, and the nucleotide sequences of corresponding primers thereof are as shown in SEQ ID No. 1 to SEQ ID No. 18. A triplex PCR detectionmethod provided by the invention can quickly and accurately detect the cytolethal distending toxins of Campylobacter, and can realize detection of a single toxin or all the three toxins selected fromthe cytolethal distending toxins A, B and C of Campylobacter in one operation, so time and effort are saved, and the detection can be completed in on shot without three PCR operations and three electrophoresis operations; a conventional single PCR method usually takes 2-3 days, and the triplex PCR detection method of the invention shortens detection time to 4 h, so work efficiency is greatly improved; and the method can be used for general investigation of the toxin types of Campylobacter, molecular epidemiological investigation and vaccine screening and detection.

Provided herein are methods for transforming a Pyrococcus furiosus with a polynucleotide. In one embodiment, the method includes contacting a P. furiosus with a polynucleotide under conditions suitable for uptake of the polynucleotide by the P. furiosus, and identifying transformants at a frequency of, for instance, at least 10³ transformants per microgram DNA. Also provided are isolated Pyrococcus furiosus having the characteristics of Pyrococcus furiosus COM1, and plasmids that include an origin of replication that functions in a Pyrococcus furiosus. The plasmid is stable in a recipient P. furiosus without selection for more than 100 generations and is structurally unchanged after replication in P. furiosus for more than 100 generations.

Porcine models for studying bacterial gastritis and gastric and duodenal ulcer disease caused by Campylobacter pathogens, such as C. coli are described, as well as methods of identifying vaccines and compounds for treating and/or preventing Campylobacter infection using the animal models. Also described are methods of preventing Campylobacter infection in swine, such as infection caused by C. coli, using immunogenic proteins and nucleic acids derived from Campylobacter pathogens, such as C. coli.

The invention provides a plankton metabolite. The plankton metabolite is obtained through taking mixed thalli of flavobacterium aquatile, rhizomonas and campylobacter as fermentation bacteria, and a water solution of algal polysaccharide as a culture medium, and fermenting. The invention further provides a plankton fermentation solution containing the plankton metabolite; the plankton metabolite and the plankton metabolite have the effects of resisting inflammations, increasing muscles and lowering lipid, remodeling a facial form and tightening skin.

The present invention provides a heat-stable and protease-resistant antibacterial activity in excretory-secretory products (ESP) of Trichuris suis. The antibacterial activity is not more than 10,000 MW; is resistant to boiling, trypsin, and pronase E; has a bactericidal mode of action; and is effective against Gram positive and Gram negative bacteria, including Escherichia coli, Campylobacter jejuni, Campylobactercoli, and Staphylococcus aureus. The antibacterial activity is useful in applications for killing or inhibiting the growth of microorganisms, in particular bacteria.

The invention provides a method and compositions for controlling food borne enteric bacterial pathogens in animals. Populations of enteropathogenic bacteria may be substantially reduced or eliminated by treatment of animals with an effective amount of 2-nitropropanol, 2-nitroethane or 2-nitroethanol. The compounds may be administered orally, providing a reduction in the populations of the enteropathogenic bacteria in the alimentary tract of the animal, or they may be applied externally onto the animal to reduce the populations of any such bacteria which may be present as contaminants on the surface of the animal. The method and compositions are particularly useful for the control of Salmonella species, enteropathogenic Escherichia coli, Campylobacter species, and Listeria monocytogenes.

Benzimidazole compounds of the general formula (I) and pharmaceutically acceptable salts or esters thereof are peptide deformylase inhibitors useful in the treatment or prevention of infections and other diseases in which peptide deformylases are involved, especially in the treatment of bacterial and parasitic infections, for example infections fully or partly caused by microorganisms belonging to Staphylococcus, Enterococcus, Streptococcus, Haemophilus, Moraxella, Escherichia, Mycobacterium, Mycoplasma, Pseudomonas, Chlamydia, Rickettsia, Klebsiella, Shigella, Salmonella, Bordetella, Clostridium, helicobacter, Campylobacter, Legionella, or Neisseria.